Literature DB >> 23233639

Are you sure this is Waldenstrom macroglobulinemia?

Irene M Ghobrial1.   

Abstract

Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder characterized by the presence of lymphoplasmacytic cells in the BM and IgM monoclonal protein in the serum. The origin of the malignant clone is thought to be a B cell arrested after somatic hypermutation in the germinal center and before terminal differentiation to plasma cells. In this review, recent advances in the genetic and epigenetic regulators of tumor progression are discussed. Risk factors include IgM-monoclonal gammopathy of undermined significance, familial disease, and immunological factors. The clinical manifestations of the disease include those related to clonal infiltration of the BM, lymph nodes, and, rarely, other sites such as pulmonary or CNS infiltration (Bing-Neel syndrome). Other manifestations are related to the IgM monoclonal protein, including hyperviscosity, cryoglobulinemia, protein-protein interactions, Ab-mediated disorders such as neuropathy, hemolytic anemia, and Schnitzler syndrome. IgM deposition in organs can lead to amyloidogenic manifestations in WM. The diagnostic workup for a patient with WM and rare presentations of WM are described herein. Prognosis of WM depends on 5 major factors in the International Staging System, including age, anemia, thrombocytopenia, β-2 microglobulin, and IgM level. The differential diagnosis of WM includes IgM-multiple myeloma, marginal zone lymphoma, mantle cell lymphoma, and follicular lymphoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233639     DOI: 10.1182/asheducation-2012.1.586

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  11 in total

1.  Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.

Authors:  Hong Zou; Rong Yang; Zhong-Xian Liao; Tian-di Qin; Ping Chen; Bei-Ying Zhang; Ying-Ping Cao; Hui-Fang Huang
Journal:  J Clin Lab Anal       Date:  2018-11-28       Impact factor: 2.352

2.  Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Authors:  Larissa Higgins; Samih H Nasr; Samar M Said; Prashant Kapoor; David Dingli; Rebecca L King; S Vincent Rajkumar; Robert A Kyle; Taxiarchis Kourelis; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Francis K Buadi; Stephen M Ansell; Wilson I Gonsalves; Carrie A Thompson; Fernando C Fervenza; Ladan Zand; Yi L Hwa; Dragan Jevremovic; Min Shi; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-30       Impact factor: 8.237

3.  WALDENSTRÖM'S MACROGLOBULINEMIA MASQUERADING AS BIRDSHOT CHORIORETINOPATHY.

Authors:  Jane S Kim; Laurence Jaworski; Dipti Patel-Donnelly; Robert B Nussenblatt; H Nida Sen
Journal:  Retin Cases Brief Rep       Date:  2017 Spring

4.  A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.

Authors:  Nelson Leung; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2016-03-18       Impact factor: 8.237

5.  Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry.

Authors:  Henrik Gregersen; Caroline Brenner Larsen; Anne Haglund; Rikke Mortensen; Niels Frost Andersen; Mette Nørgaard
Journal:  Clin Epidemiol       Date:  2013-08-27       Impact factor: 4.790

Review 6.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

Review 7.  New developments in the management of Waldenström macroglobulinemia.

Authors:  Jithma P Abeykoon; Uday Yanamandra; Prashant Kapoor
Journal:  Cancer Manag Res       Date:  2017-03-10       Impact factor: 3.989

Review 8.  How to manage Waldenstrom's macroglobulinemia.

Authors:  C Buske; V Leblond
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528

Review 9.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09

10.  Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.

Authors:  Daeun Ryu; Hee Jin Kim; Je-Gun Joung; Hae-Ock Lee; Joon Seol Bae; Seok Jin Kim; Haesu Kim; Woong-Yang Park; Kihyun Kim
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.